Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 12/20 | 0.65 |
| ▸ | CD63 | P08962 | 3/20 | 0.65 |
| ▸ | AURKA | O14965 | 8/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14106210 | 0.92 | SYK (0.65) | SYKCD63AURKA | |
| SCHEMBL4838535 | 0.90 | AURKA (0.56) | SYKCD63AURKA | |
| SCHEMBL2216977 | 0.81 | AURKA (0.77) | SYKCD63AURKA | |
| SCHEMBL2476104 | 0.81 | SYK (0.69) | SYK | |
| SCHEMBL4838189 | 0.81 | SYK (0.65) | SYKCD63AURKA | |
| SCHEMBL12514839 | 0.81 | AURKA (0.79) | SYKCD63AURKA | |
| SCHEMBL2482928 | 0.80 | SYK (0.71) | SYKCD63 | |
| SCHEMBL4835147 | 0.80 | SYK (0.67) | SYKCD63AURKA | |
| SCHEMBL4830920 | 0.79 | SYK (0.65) | SYKCD63AURKA | |
| SCHEMBL2481780 | 0.78 | SYK (1.00) | SYKCD63AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080182849-A1 | Certain Heterocyclic Substituted Imidazo[1,2-A]Pyrazin-8-Ylamines And Methods Of Inhibition Of Bruton's Tyrosine Kinase By Such Compounds | CURRIE KEVIN S | 2008-07-31 | — | — | US | disclosed |
| US-7393848-B2 | Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds | CGI PHARMACEUTICALS, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-20050101604-A1 | Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of bruton's tyrosine kinase by such compounds | GILEAD CONNECTICUT, INC. | 2005-05-12 | — | — | US | disclosed |
| WO-2005005429-A1 | CERTAIN HETEROCYCLIC SUBSTITUTED IMIDAZO[1,2-A]PYRAZIN-8-YLAMINES AND METHODS OF INHIBITION OF BRUTON’S TYROSINE KINASE BY SUCH COMPOUNDS | CELLULAR GENOMICS, INC. (US) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101604-A1 | Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of bruton's tyrosine kinase by such compounds | BTK, SYK, LYN | SYK 2/4885CD63 2678/4885AURKA 551/4885 |
| US-20080182849-A1 | Certain Heterocyclic Substituted Imidazo[1,2-A]Pyrazin-8-Ylamines And Methods Of Inhibition Of Bruton's Tyrosine Kinase By Such Compounds | BTK, SYK, LYN | SYK 2/4885CD63 2443/4885AURKA 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.